Kromasil^® - GLP-1 agonist purification strategy

With the number of people around the world diagnosed with diabetes increasing, the need for adequate treatments are also on the rise. At the same time, many of the substances used in the production of type 2 diabetes pharmaceuticals are challenging to purify in an efficient way and to the level needed to be approved for safe use by patients. This is where Nouryon’s high-performing Kromasil^® chromatography solutions now support the pharmaceutical industry.

“With our efficient purification strategy, it is possible to reach the 99.5 % purity needed for regulatory approval in only two steps compared to three or four steps, which is often the case in the industry today. This translates into greatly improved efficiency and productivity for our customers,” said Patrick Wilhelm, Vice President of Inorganic Specialties at Nouryon.

The new purification toolbox for GLP-1 (glucagon-like peptide-1) agonists, such as liraglutide, enables solutions that are tailor-made to the different conditions in our customers’ production processes and includes procedures that greatly improve the Kromasil^® media lifetime by increasing the number of purification cycles that can be carried out. This enables our customers to significantly reduce the time needed to optimize their purification process and, as a result, allows a more efficient process.

“Type 2 diabetes patients rely on their medicine every day and, in many cases, it’s a lifelong treatment. We are proud to be able to provide our pharmaceutical customers with solutions that contribute to the promotion of well-being to ensure healthy lives,” said Wilhelm.

If you would like to know more, download our brochure or get in touch using the contact options below.